{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T10:55:23Z","timestamp":1791111323869,"version":"4.1.0"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,4]]},"DOI":"10.1097\/01.jcp.0000203199.88581.c3","type":"journal-article","created":{"date-parts":[[2006,4,20]],"date-time":"2006-04-20T05:10:55Z","timestamp":1145509855000},"page":"135-142","source":"Crossref","is-referenced-by-count":35,"title":["Combined Effects of Itraconazole and CYP2D6*10 Genetic Polymorphism on the Pharmacokinetics and Pharmacodynamics of Haloperidol in Healthy Subjects"],"prefix":"10.1097","volume":"26","author":[{"given":"Ji-Young","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Hong","family":"Shon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoung-Ah","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun-Ju","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joo-Cheol","family":"Shim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Ran","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In-June","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Gook","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20210128","first-page":"245","article-title":"Studies on serum protein binding of haloperidol.","volume":"21","author":"Forsman","year":"1977","journal-title":"Curr Ther Res Clin Exp"},{"key":"R2-5-20210128","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/00004714-199206000-00004","article-title":"Haloperidol metabolism in psychiatric patients: importance of glucuronidation and carbonyl reduction.","volume":"12","author":"Someya","year":"1992","journal-title":"J Clin Psychopharmacol"},{"key":"R3-5-20210128","first-page":"159","article-title":"Metabolism of haloperidol: clinical implications and unanswered questions.","volume":"14","author":"Tsang","year":"1994","journal-title":"J Clin Psychopharmacol"},{"key":"R4-5-20210128","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2165\/00003088-199937060-00001","article-title":"Pharmacokinetics of haloperidol: an update.","volume":"37","author":"Kudo","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"R5-5-20210128","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/00007691-199204000-00003","article-title":"Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype.","volume":"14","author":"Llerena","year":"1992","journal-title":"Ther Drug Monit"},{"key":"R6-5-20210128","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1046\/j.1440-1819.1999.00611.x","article-title":"The effect of cytochrome P450 2D6 genotypes on haloperidol metabolism: a preliminary study in a psychiatric population.","volume":"53","author":"Someya","year":"1999","journal-title":"Psychiatry Clin Neurosci"},{"key":"R7-5-20210128","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0006-3223(85)90087-3","article-title":"Carbamazepine-induced reduction of blood levels of haloperidol in chronic schizophrenia.","volume":"20","author":"Kidron","year":"1985","journal-title":"Biol Psychiatry"},{"key":"R8-5-20210128","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00004714-199606000-00010","article-title":"Effect of rifampin on the plasma concentration and the clinical effect of haloperidol concomitantly administered to schizophrenic patients.","volume":"16","author":"Kim","year":"1996","journal-title":"J Clin Psychopharmacol"},{"key":"R9-5-20210128","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/00004714-199904000-00010","article-title":"Effects of itraconazole on the steady-state plasma concentrations of haloperidol and its reduced metabolite in schizophrenic patients: in vivo evidence of the involvement of CYP3A4 for haloperidol metabolism.","volume":"19","author":"Yasui","year":"1999","journal-title":"J Clin Psychopharmacol"},{"key":"R10-5-20210128","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1046\/j.1365-2125.1997.t01-1-00629.x","article-title":"Characterization of the cytochrome P450 isoenzymes involved in the in vitro N-dealkylation of haloperidol.","volume":"44","author":"Pan","year":"1997","journal-title":"Br J Clin Pharmacol"},{"key":"R11-5-20210128","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1067\/mcp.2002.127494","article-title":"The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment.","volume":"72","author":"Brockmoller","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"R12-5-20210128","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/00008571-200110000-00002","article-title":"Unravelling the functional genomics of the human CYP2D6 gene locus.","volume":"11","author":"Ingelman-Sundberg","year":"2001","journal-title":"Pharmacogenetics"},{"key":"R13-5-20210128","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/00041444-199909000-00006","article-title":"Genetic association between cytochrome P-450 2D6 gene polymorphism and plasma concentration of haloperidol in Japanese schizophrenics.","volume":"9","author":"Shibata","year":"1999","journal-title":"Psychiatr Genet"},{"key":"R14-5-20210128","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s002280100372","article-title":"Risperidone metabolism in relation to CYP2D610 allele in Korean schizophrenic patients.","volume":"57","author":"Roh","year":"2001","journal-title":"Eur J Clin Pharmacol"},{"key":"R15-5-20210128","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1046\/j.0306-5251.2001.01411.x","article-title":"Influence of the CYP2D610 allele on the metabolism of mexiletine by human liver microsomes.","volume":"52","author":"Senda","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"R16-5-20210128","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1046\/j.1365-2125.1999.00913.x","article-title":"Effect of the CYP2D610 genotype on venlafaxine pharmacokinetics in healthy adult volunteers.","volume":"47","author":"Fukuda","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"R17-5-20210128","first-page":"1040","article-title":"Effect of CYP2D610 genotype on propafenone pharmacodynamics in Chinese patients with ventricular arrhythmia.","volume":"23","author":"Cai","year":"2002","journal-title":"Acta Pharmacol Sin"},{"key":"R18-5-20210128","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2165\/00003088-200038020-00002","article-title":"Effects of the antifungal agents on oxidative drug metabolism.","volume":"38","author":"Venkatakrishnan","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"R19-5-20210128","first-page":"452","article-title":"Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation.","volume":"46","author":"Johansson","year":"1994","journal-title":"Mol Pharmacol"},{"key":"R20-5-20210128","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/01213011-199912000-00002","article-title":"Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data.","volume":"9","author":"Gaedigk","year":"1999","journal-title":"Pharmacogenetics"},{"key":"R21-5-20210128","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0378-4347(95)00431-9","article-title":"Quantification of dextromethorphan and metabolites: a dual phenotypic marker for cytochrome P450 3A4\/5 and 2D6 activity.","volume":"678","author":"Jones","year":"1996","journal-title":"J Chromatogr B Biomed Appl"},{"key":"R22-5-20210128","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/j.0954-6820.1920.tb18267.x","article-title":"Die Systoledauer im Elektrokardiogramm bei normalen Menschen und bei Herzkranken.","volume":"53","author":"Fridericia","year":"1920","journal-title":"Acta Med Scand"},{"key":"R23-5-20210128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","article-title":"The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients.","volume":"334","author":"Lingjaerde","year":"1987","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"R24-5-20210128","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia.","volume":"154","author":"Barnes","year":"1989","journal-title":"Br J Psychiatry"},{"key":"R25-5-20210128","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/00008571-199404000-00004","article-title":"The cytochrome P450 CYP2D6 allelic variant CYP2D6J and related polymorphisms in a European population.","volume":"4","author":"Armstrong","year":"1994","journal-title":"Pharmacogenetics"},{"key":"R26-5-20210128","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1067\/mcp.2002.125783","article-title":"Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans.","volume":"72","author":"Gaedigk","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"R27-5-20210128","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/00008571-200108000-00003","article-title":"Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates.","volume":"11","author":"Ramamoorthy","year":"2001","journal-title":"Pharmacogenetics"},{"key":"R28-5-20210128","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1046\/j.1365-2125.2000.00209.x","article-title":"Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes.","volume":"50","author":"Kubota","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"R29-5-20210128","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1046\/j.0306-5251.2001.01437.x","article-title":"Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients.","volume":"52","author":"Roh","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"R30-5-20210128","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0278-5846(02)00314-7","article-title":"Effects of age and the CYP2D610 allele on the plasma haloperidol concentration\/dose ratio.","volume":"27","author":"Ohara","year":"2003","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R31-5-20210128","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0009-9236(99)70108-6","article-title":"Effects of the CYP2D610 allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia.","volume":"65","author":"Mihara","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"R32-5-20210128","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1128\/AAC.46.1.160-165.2002","article-title":"Interaction of common azole antifungals with P glycoprotein.","volume":"46","author":"Wang","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"R33-5-20210128","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1211\/0022357043969","article-title":"Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds-implications for pharmacokinetics of selected substrates.","volume":"56","author":"El Ela","year":"2004","journal-title":"J Pharm Pharmacol"},{"key":"R34-5-20210128","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0024-3205(02)01680-6","article-title":"In vitro P-glycoprotein affinity for atypical and conventional antipsychotics.","volume":"71","author":"Boulton","year":"2002","journal-title":"Life Sci"},{"key":"R35-5-20210128","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/BF00174062","article-title":"Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance.","volume":"90","author":"Jann","year":"1986","journal-title":"Psychopharmacology"},{"key":"R36-5-20210128","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/0006-3223(90)90488-N","article-title":"The influence of cigarette smoking on haloperidol pharmacokinetics.","volume":"28","author":"Miller","year":"1990","journal-title":"Biol Psychiatry"},{"key":"R37-5-20210128","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/00008571-199408000-00005","article-title":"The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes.","volume":"4","author":"Bock","year":"1994","journal-title":"Pharmacogenetics"},{"key":"R38-5-20210128","first-page":"413","article-title":"Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation describing the phenotype in the CYP1A2 gene.","volume":"3","author":"Nakajima","year":"1994","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"R39-5-20210128","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/0006-291X(91)91228-5","article-title":"Identification of potentially neurotoxic pyridinium metabolite in the urine of schizophrenic patients treated with haloperidol.","volume":"181","author":"Subramanyam","year":"1991","journal-title":"Biochem Biophys Res Commun"},{"key":"R40-5-20210128","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0009-8981(00)00266-7","article-title":"Analysis of the metabolism of haloperidol (HP) and its neurotoxic pyridinium metabolite (HPP+) in patients with drug-induced parkinsonism.","volume":"298","author":"Iwahashi","year":"2000","journal-title":"Clin Chim Acta"},{"key":"R41-5-20210128","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1021\/tx960001y","article-title":"Studies on the conversion of haloperidol and its tetrahydropyridine dehydration product to potentially neurotoxic pyridinium metabolites by human liver microsomes.","volume":"9","author":"Usuki","year":"1996","journal-title":"Chem Res Toxicol"},{"key":"R42-5-20210128","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1023\/A:1026317929335","article-title":"Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol.","volume":"17","author":"Fang","year":"1997","journal-title":"Cell Mol Neurobiol"},{"key":"R43-5-20210128","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S0193-953X(18)30166-7","article-title":"Neuroleptic-induced acute extrapyramidal syndromes and tardive dyskinesia.","volume":"16","author":"Casey","year":"1993","journal-title":"Psychiatr Clin North Am"},{"key":"R44-5-20210128","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0014-2999(90)90260-D","article-title":"Metabolites of haloperidol display preferential activity at sigma receptors compared to dopamine D-2 receptors.","volume":"177","author":"Bowen","year":"1990","journal-title":"Eur J Pharmacol"},{"key":"R45-5-20210128","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1176\/ajp.156.6.885","article-title":"Persistence of haloperidol in human brain tissue.","volume":"156","author":"Kornhuber","year":"1999","journal-title":"Am J Psychiatry"},{"key":"R46-5-20210128","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/096032719101000110","article-title":"Life-threatening ventricular arrhythmia (torsades de pointes) after haloperidol overdose.","volume":"10","author":"Henderson","year":"1991","journal-title":"Human Exp Toxicol"},{"key":"R47-5-20210128","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0033-3182(95)71609-7","article-title":"The association between intravenous haloperidol and torsade de pointes. Three cases and a literature review.","volume":"36","author":"Hunt","year":"1995","journal-title":"Psychosomatics"},{"key":"R48-5-20210128","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/00004714-198612000-00018","article-title":"Torsades de pointes ventricular tachyarrhythmia associated with haloperidol.","volume":"6","author":"Fayer","year":"1986","journal-title":"J Clin Psychopharmacol"},{"key":"R49-5-20210128","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1378\/chest.98.2.482","article-title":"Haloperidol-induced torsade de pointes.","volume":"98","author":"Kriwisky","year":"1990","journal-title":"Chest"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00004714-200604000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:26:03Z","timestamp":1785857163000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00004714-200604000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006]]}},"URL":"https:\/\/doi.org\/10.1097\/01.jcp.0000203199.88581.c3","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2006,4]]}}}